GKOS
GLAUKOS Corp
NYSE · Healthcare · Medical - Devices · US
$167.25
−1.84%Price chart
Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8Sep 11
ValuationView details →
P/E (Fwd)
1090.8x
EV/EBITDA
−68.1x
Market Cap
$9.87B
MomentumView details →
1D Return
−1.84%
YTD Return
+50.40%
RSI (14)
42.3
ValuationView details →
P/E (Fwd)
1090.8x
EV/EBITDA
−68.1x
Market Cap
$9.87B
RSI (14)
42.3
MomentumView details →
1D Return
−1.84%
YTD Return
+50.40%
SummaryUpdated Jun 1, 2026
Glaukos Corporation (NASDAQ:GKOS) is a specialized ophthalmic medical technology and pharmaceutical company founded in 1998 and headquartered in San Clemente, California. The company went public in June 2015 and has established itself as a pioneer in minimally invasive glaucoma surgery (MIGS) and innovative ocular therapeutics. Glaukos focuses on developing and commercializing novel therapies for treating glaucoma, corneal disorders, and retinal diseases, with a particular emphasis on what it calls "interventional glaucoma" - a proactive approach to treating eye pressure and preventing vision loss before significant damage occurs.
Similar companies
Latest newsMore news →
Glaukos Corporation reported its second quarter 2026 financial results, posting a net loss of $0.14 per share, which beat the Zacks Consensus Estimate of a loss of $0.28 per share and improved from a loss of $0.24 per share in the same quarter a year ago.44d agoGlaukos completed patient enrollment in its U.S. 510(k) pivotal study for the PRESERFLO MicroShunt in adult patients with primary open-angle glaucoma.47d ago